Saturday, February 27, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

This Atomically Thin Detector Could Become a Biotech Breakthrough

by Global Biodefense Staff
May 25, 2020
This Atomically Thin Detector Could Become a Biotech Breakthrough

Artist’s rendition of a carbon nanotube COVID-19 detector. (Courtesy of: Zettl Research Group/Berkeley Lab)

A technology spun from carbon nanotube sensors discovered 20 years ago by Lawrence Berkeley National Laboratory scientists could one day help healthcare providers test patients for COVID-19, the disease caused by the coronavirus SARS-CoV-2.

When Alex Zettl, Marvin Cohen, and their research teams at Berkeley Lab first demonstrated ultrasensitive oxygen sensors devised from carbon nanotubes – hollow carbon wires with walls no thicker than an atom- they envisioned a broad spectrum of applications, such as gas-leak detectors or air- and water-pollution detectors.

Subsequent studies out of Zettl’s lab revealed that carbon nanotubes – or CNTs – could also be used to detect proteins or carbohydrates at the level of single cells for biological and medical applications. “CNTs’ exquisite chemical sensitivity had dramatic life-science implications that could benefit society,” Zettl said.

But since Zettl normally investigates atomically thin materials known as nanomaterials for the Department of Energy’s “Novel sp2-Bonded Materials and Related Nanostructures” program, his lab is set up for launching exciting new experiments in quantum physics, not new applications for entrepreneurial startups.

So in 2000, Zettl and Cohen, who are both senior faculty scientists in Berkeley Lab’s Materials Sciences Division and physics professors at UC Berkeley, branched out into the world of commercial spin-offs by co-founding the Emeryville-based biotech company Nanomix Inc. They currently sit on the company’s board of directors – Zettl participates as an adviser, and Cohen as a member.

Today, the company is one of many U.S. companies vying for FDA Emergency Use Authorization (EUA) to deploy new diagnostic tests for COVID-19, the infectious disease caused by the coronavirus SARS-CoV-2.

Last month, the company was awarded approximately $570,000 in funding from the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to develop disposable cartridges that test for antigens in nasal swab samples, and for antibodies to the coronavirus in blood samples.

Patient samples loaded onto the cartridges are analyzed by the Nanomix “eLab,” a handheld testing device the company first developed more than five years ago in response to the Ebola virus epidemic.

The cartridges rely on tiny carbon biosensors modeled after the Zettl and Cohen labs’ groundbreaking carbon nanotube technology to detect coronavirus antigens during the early stages of a current infection. In addition, the cartridges can test for antibodies the immune system builds up as part of our body’s natural defense mechanism against a previous SARS-CoV-2 infection. The company says the eLab system can produce test results in about 15 minutes.

If granted FDA Emergency Use Authorization, the company hopes to have COVID-19-ready eLab products available for healthcare providers in June, and to scale up its supply and production capacity to provide hundreds of thousands of test kits, said Nanomix President and CEO David Ludvigson.

Tags: AwardsBARDABiotechnologyCOVID-19Editor PickInnovationNanotechSARS-CoV-2

Related Posts

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response
Historical Reflections

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters
Biosecurity

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate
Historical Reflections

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?
Infectious Diseases

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021
Load More

Latest News

First Human Trial of COVID-19 Vaccine Finds it is Safe and Induces Rapid Immune Response

COVID-19 Vaccination: What We Can Learn From the Great Polio Vaccine Heist of 1959

February 24, 2021
Sign on street in Conakry that says Ebola in large letters

Why Ebola is Back in Guinea and Why the Response Must Be Different This Time

February 24, 2021
How Roald Dahl Became a Passionate Vaccine Advocate

How Roald Dahl Became a Passionate Vaccine Advocate

February 23, 2021
How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

How Do We Know the COVID Vaccine Won’t Have Long-Term Side-Effects?

February 23, 2021

Upcoming Events

Mar 1
Virtual Event
All day

Rare Disease Day at NIH 2021 – Virtual Conference

Mar 2
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 2
Virtual Event
4:00 pm - 6:00 pm

RNA Viruses: How They Do What They Do

Mar 2
Virtual Event
5:00 pm - 7:00 pm

COVID Seminar Series – Hindsight is 2020

Mar 4
Virtual Event
10:00 am - 1:30 pm

Vulnerabilities in U.S. Chemical Weapons Detection, Identification, and Tracing

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC